Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2019, Article ID 3065818, 14 pages
https://doi.org/10.1155/2019/3065818
Research Article

Anticancer Effects of Emodin on HepG2 Cell: Evidence from Bioinformatic Analysis

1The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China
2Guangzhou University of Chinese Medicine, Guangzhou, China
3Stomatological Hospital of Shandong University, Shandong, China
4Jinan Stomatological Hospital, Shandong, China
5Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, China

Correspondence should be addressed to Ying Tang; moc.361@84744152881

Received 9 January 2019; Revised 31 March 2019; Accepted 23 April 2019; Published 19 May 2019

Academic Editor: Michael Linnebacher

Copyright © 2019 Rui-sheng Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Bjørge, J. Hakulinen, O. K. Vintermyr et al., “Ascitic complement system in ovarian cancer,” British Journal of Cancer, vol. 92, no. 5, pp. 895–905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Bläker, M. Schmitz, A. Gocht et al., “Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas,” Journal of Hepatology, vol. 41, no. 1, pp. 112–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Bruix, S. Qin, P. Merle et al., “Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet, vol. 389, no. 10064, pp. 56–66, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Cerami, J. Gao, U. Dogrusoz et al., “The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data,” Cancer Discovery, vol. 2, no. 5, pp. 401–404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Cha, L. Qiu, C. Chen, Y. Wen, and M. Hung, “Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth,” Cancer Research, vol. 65, no. 6, pp. 2287–2295, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Corrales, D. Ajona, S. Rafail et al., “Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression,” The Journal of Immunology, vol. 189, no. 9, pp. 4674–4683, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Coutinho-Silva, L. Stahl, K.-K. Cheung et al., “P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: Effects of extracellular nucleotides on apoptosis and cell proliferation,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 288, no. 5, pp. G1024–G1035, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. V. De Sá, M. L. Corrêa-Giannella, M. C. Machado et al., “Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas,” Endocrine-Related Cancer, vol. 13, no. 1, pp. 69–78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Dong, B. Ni, J. Fu et al., “Emodin induces apoptosis in human hepatocellular carcinoma HepaRG cells via the mitochondrial caspasedependent pathway,” Oncology Reports, vol. 40, no. 4, pp. 1985–1993, 2018. View at Google Scholar · View at Scopus
  10. G. R. Dubyak, “Knock-out mice reveal tissue-specific roles of P2Y receptor subtypes in different epithelia,” Molecular Pharmacology, vol. 63, no. 4, pp. 773–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. B. El-Khoueiry, B. Sangro, T. Yau et al., “Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial,” The Lancet, vol. 389, no. 10088, pp. 2492–2502, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Franceschini, D. Szklarczyk, S. Frankild et al., “STRING v9.1: protein-protein interaction networks, with increased coverage and integration,” Nucleic Acids Research, vol. 41, no. 1, pp. D808–D815, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Gancz and Z. Fishelson, “Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development,” Molecular Immunology, vol. 46, no. 14, pp. 2794–2800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Gao, B. A. Aksoy, U. Dogrusoz, and ETAL, “Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal,” Science Signaling, vol. 6, p. 11, 2013. View at Google Scholar
  15. J. Gminski, J. Mykala-Ciesla, M. Machalski et al., “Immunoglobulins and complement components levels in patients with lung cancer,” Romanian Journal of Internal Medicine, vol. 30, pp. 39–44, 1992. View at Google Scholar
  16. Y. A. Goo and D. R. Goodlett, “Advances in proteomic prostate cancer biomarker discovery,” Journal of Proteomics, vol. 73, no. 10, pp. 1839–1850, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. X. He, Y. Wang, W. Zhang et al., “Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ -MALDI-MS/MS,” Neoplasma, vol. 61, no. 1, pp. 17–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Horckmans, E. Léon-Gómez, B. Robaye et al., “Gene deletion of P2Y4 receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 7, pp. 835–843, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C.-M. Hsu, Y.-A. Hsu, Y. Tsai et al., “Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells,” Biochemical and Biophysical Research Communications, vol. 392, no. 4, pp. 473–478, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. P. H. Huang, C. Y. Huang, M. C. Chen et al., “Emodin and aloe-emodin suppress breast cancer cell proliferation through ER alpha inhibition,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 376123, 12 pages, 2013. View at Publisher · View at Google Scholar
  21. K. Ikeda, M. Kudo, S. Kawazoe et al., “Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma,” Journal of Gastroenterology, vol. 52, no. 4, pp. 512–519, 2017. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Jia, F. Yu, J. Wang et al., “Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs,” Breast Cancer Research and Treatment, vol. 148, no. 2, pp. 291–302, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. E. U. Koc, T. Ozgur, O. Yerci et al., “Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5) expression in hepatocellular carcinoma,” Hepato-Gastroenterology, vol. 60, no. 127, pp. 1693–1697, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Kim, B. Langmead, and S. L. Salzberg, “HISAT: a fast spliced aligner with low memory requirements,” Nature Methods, vol. 12, no. 4, pp. 357–360, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Langmead and S. L. Salzberg, “Fast gapped-read alignment with Bowtie 2,” Nature Methods, vol. 9, no. 4, pp. 357–359, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Li and C. N. Dewey, “RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome,” BMC Bioinformatics, vol. 12, p. 323, 2011. View at Google Scholar
  27. L. Wang, Z. Feng, X. Wang, and X. Zhang, “DEGseq: an R package for identifying differentially expressed genes from RNA-seq data,” Bioinformatics, vol. 26, no. 1, pp. 136–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019. View at Publisher · View at Google Scholar
  29. M. E. Smoot, K. Ono, J. Ruscheinski, P. L. Wang, and T. Ideker, “Cytoscape 2.8: new features for data integration and network visualization,” Bioinformatics, vol. 27, no. 3, pp. 431-432, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Nepusz, H. Yu, and A. Paccanaro, “Detecting overlapping protein complexes in protein-protein interaction networks,” Nature Methods, vol. 9, no. 5, pp. 471-472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Li, Q. Lei, S. Zhang, L. Kong, and B. Qin, “Screening and identification of key biomarkers in hepatocellular carcinoma: evidence from bioinformatic analysis,” Oncology Reports, vol. 38, no. 5, pp. 2607–2618, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Wurmbach, Y.-B. Chen, G. Khitrov et al., “Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma,” Hepatology, vol. 45, no. 4, pp. 938–947, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Mazzocca, F. Dituri, F. De Santis et al., “Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity of hepatocellular carcinoma,” Cancer Research, vol. 75, no. 3, pp. 532–543, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Z. Wiley, K. Sriram, W. Liang et al., “GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells,” The FASEB Journal, vol. 32, no. 3, pp. 1170–1183, 2018. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Ren and L. Zhang, “Effects of ovarian cancer G protein coupled receptor 1 on the proliferation, migration, and adhesion of human ovarian cancer cells,” Chinese Medical Journal, vol. 124, no. 9, pp. 1327–1332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Raman, W. Chen, and M. H. Cobb, “Differential regulation and properties of MAPKs,” Oncogene, vol. 26, no. 22, pp. 3100–3112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Kolev, L. Towner, and R. Donev, “Complement in cancer and cancer immunotherapy,” Archivum Immunologiae et Therapia Experimentalis, vol. 59, no. 6, pp. 407–419, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. L. A. Trouw, M. C. Pickering, and A. M. Blom, “The complement system as a potential therapeutic target in rheumatic disease,” Nature Reviews Rheumatology, vol. 13, no. 9, pp. 538–547, 2017. View at Publisher · View at Google Scholar · View at Scopus
  39. M. J. Rutkowski, M. E. Sughrue, A. J. Kane, S. A. Mills, and A. T. Parsa, “Cancer and the complement cascade,” Molecular Cancer Research, vol. 8, no. 11, pp. 1453–1465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Yamada, M. Stoffel, R. Espinosa et al., “Human somatostatin receptor genes: localization to human chromosomes 14, 17, and 22 and identification of simple tandem repeat polymorphisms,” Genomics, vol. 15, no. 2, pp. 449–452, 1993. View at Publisher · View at Google Scholar · View at Scopus
  41. S. M. Pasternack, I. Von Kügelgen, K. A. Aboud et al., “G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth,” Nature Genetics, vol. 40, no. 3, pp. 329–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. K. T. Weiss, M. Fante, G. Köhl et al., “Proton-sensing G protein-coupled receptors as regulators of cell proliferation and migration during tumor growth and wound healing,” Experimental Dermatology, vol. 26, no. 2, pp. 127–132, 2017. View at Publisher · View at Google Scholar · View at Scopus